Crossroads Cancer Center
Effingham, Illinois, United States
Cancer treatment center in Effingham, Illinois
905 Medical Park Dr, Effingham, IL 62401
About Crossroads Cancer Center
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
National Cancer Institute (NCI)
138
SWOG Cancer Research Network
58
Alliance for Clinical Trials in Oncology
43
ECOG-ACRIN Cancer Research Group
24
NRG Oncology
24
Wake Forest University Health Sciences
6
NSABP Foundation Inc
5
GOG Foundation
4
Gynecologic Oncology Group
4
Children's Oncology Group
3
Eastern Cooperative Oncology Group
2
Clinical Trials at Crossroads Cancer Center
During the past decade, Crossroads Cancer Center conducted 218 clinical trials. In the 10-year time frame, 218 clinical trials started and 105 clinical trials were completed, i.e. on
average, 48.2% percent of trials that started reached the finish line to date. In the past 5 years, 75 clinical trials started and 74 clinical trials were completed. i.e. 98.7%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
1998-12-01
2025-10-01
Active, not recruiting
1,150
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2005-05-01
Completed
520
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
2004-09-01
2009-10-01
Completed
1,783
S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone
2007-03-01
2014-01-01
Completed
85
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
2007-06-01
2012-11-01
Terminated
72
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
2007-12-06
Active, not recruiting
1,052
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2008-08-08
Active, not recruiting
403
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
2008-03-01
2014-02-25
Completed
134
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Crossroads Cancer Center" #1 sponsor was "National Cancer Institute (NCI)" with 138 trials, followed by "SWOG Cancer Research Network" with 58 trials
sponsored, "Alliance for Clinical Trials in Oncology" with 43 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 24 trials sponsored and "NRG Oncology"
with 24 trials sponsored. Other sponsors include 29 different institutions and
companies that sponsored additional 20 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Crossroads Cancer Center"
#1 collaborator was "National Cancer Institute (NCI)" with 169 trials as a collaborator, "NRG Oncology" with 34 trials as a collaborator, "Canadian Cancer Trials Group" with 14 trials as a collaborator, "Millennium Pharmaceuticals, Inc." with 3 trials as a collaborator and "Astellas Pharma US, Inc." with 2 trials as a collaborator. Other collaborators include 43 different institutions and companies that were
collaborators in the rest 44 trials.
Clinical Trials Conditions at Crossroads Cancer Center
According to Clinical.Site data, the most researched conditions in "Crossroads Cancer Center" are
"Stage IV Lung Cancer AJCC v8" (14 trials), "Breast Cancer" (10 trials), "Recurrent Lung Non-Small Cell Carcinoma" (10 trials), "Recurrent Ovarian Carcinoma" (10 trials) and "Recurrent Squamous Cell Lung Carcinoma" (10 trials). Many other conditions were trialed in "Crossroads Cancer Center" in a lesser frequency.
Clinical Trials Intervention Types at Crossroads Cancer Center
Most popular intervention types in "Crossroads Cancer Center" are "Drug" (247 trials), "Other" (193 trials), "Biological" (119 trials), "Procedure" (86 trials) and "Radiation" (65 trials). Other intervention types were less common.
The name of intervention was led by "Quality-of-Life Assessment" (85 trials), "Laboratory Biomarker Analysis" (76 trials), "Questionnaire Administration" (61 trials), "Computed Tomography" (47 trials) and "Biospecimen Collection" (44 trials). Other intervention names were less common.
Clinical Trials Genders at Crossroads Cancer Center
The vast majority of trials in "Crossroads Cancer Center" are
255 trials for "All" genders, 46 trials for "Female" genders and 20 trials for "Male" genders.
Clinical Trials Status at Crossroads Cancer Center
Currently, there are NaN active trials in "Crossroads Cancer Center".
undefined are not yet recruiting,
107 are recruiting,
134 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 57 completed trials in Crossroads Cancer Center,
11 suspended trials,
and 11 terminated clinical trials to date.
Out of the total trials that were conducted in Crossroads Cancer Center, 13 "Phase 1"
clinical trials were conducted, 167 "Phase 2" clinical
trials and 158 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 8 trials that are defined as “Not Applicable".